Merrimack To Present At The Oppenheimer 24th Annual Healthcare Conference

CAMBRIDGE, Mass., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Robert Mulroy, President & CEO, is scheduled to present at the Oppenheimer 24 th Annual Healthcare Conference on Wednesday, December 11, 2013 at 8:55 a.m. (ET) at the Crowne Plaza Hotel in New York.   

A live webcast of the presentation can be accessed by visiting the Investors section of Merrimack's website at investors.merrimackpharma.com.  A replay of the webcast will be archived on Merrimack's website for two weeks following the presentation.

About Merrimack

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development. For more information, please visit Merrimack's website at  www.merrimackpharma.com.

Forward-looking statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
CONTACT: Investor Contact:         Geoffrey Grande, CFA         Merrimack Pharmaceuticals         617-441-7602         ggrande@merrimackpharma.com                  Media Contact:         Dana Robie         Merrimack Pharmaceuticals         617-441-7408         drobie@merrimackpharma.com